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In 2011, following severe flooding in Eastern Australia, an unprecedented epidemic of equine encephalitis occurred
in South-Eastern Australia, caused by Murray Valley encephalitis virus (MVEV) and a new variant strain of Kunjin virus,
a subtype of West Nile virus (WNVKUN). This prompted us to assess whether a delta inulin-adjuvanted, inactivated cell
culture-derived Japanese encephalitis virus (JEV) vaccine (JE-ADVAX™) could be used in horses, including pregnant
mares and foals, to not only induce immunity to JEV, but also elicit cross-protective antibodies against MVEV and
WNVKUN. Foals, 74–152 days old, received two injections of JE-ADVAX™. The vaccine was safe and well-tolerated
and induced a strong JEV-neutralizing antibody response in all foals. MVEV and WNVKUN antibody cross-reactivity
was seen in 33% and 42% of the immunized foals, respectively. JE-ADVAX™ was also safe and well-tolerated in
pregnant mares and induced high JEV-neutralizing titers. The neutralizing activity was passively transferred to their foals
via colostrum. Foals that acquired passive immunity to JEV via maternal antibodies then were immunized with
JE-ADVAX™ at 36–83 days of age, showed evidence of maternal antibody interference with low peak antibody titers
post-immunization when compared to immunized foals of JEV-naïve dams. Nevertheless, when given a single
JE-ADVAX™ booster immunization as yearlings, these animals developed a rapid and robust JEV-neutralizing antibody
response, indicating that they were successfully primed to JEV when immunized as foals, despite the presence of
maternal antibodies. Overall, JE-ADVAX™ appears safe and well-tolerated in pregnant mares and young foals and
induces protective levels of JEV neutralizing antibodies with partial cross-neutralization of MVEV and WNVKUN.Introduction
Flaviviruses of the Japanese encephalitis virus (JEV) sero-
complex are amongst the most important encephalitic vi-
ruses worldwide, affecting humans, wild birds, and several
mammalian species, including domestic animal species
such as horses. JEV is the leading cause of viral encephal-
itis in Asia, where 2–3 billion people are at risk of con-
tracting the disease [1,2]. Annually, ~35 000 cases of JE
are reported with a case fatality rate of nearly 30% and
more than 50% of the survivors having neurological* Correspondence: h.bielefeldtohmann1@uq.edu.au
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article, unless otherwise stated.sequelae. Clinical manifestations vary and may include
fever, headache, a change in mental status, seizures,
tremors, generalised paresis, hypertonia and loss of coord-
ination [3]. The clinical course in horses resembles that
found in humans [4-7] with the majority of equine JEV in-
fections being subclinical [8]. There is an estimated in-
cidence of JE of 0.05% of JEV infections with a JE case
fatality rate of ~50%. Treatment of JE patients, whether
humans or horses, in the absence of availability of anti-
viral compounds, is supportive and the best means of
preventing JE is immunization [9].
An inactivated JEV vaccine, developed in Japan in the
1960s (JE-VAX), dramatically reduced the number of hu-
man and equine cases of JE in that country [10]. However,
this vaccine ceased to be manufactured in 2005, due toed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with subsequent JEV vaccines being developed based on
inactivated virus grown in cell culture [10,11].
Vaccination of thoroughbred horses against JEV is
mandatory in several Asian countries. However, in many
countries there is currently no widely available and ap-
proved equine JEV vaccine resulting in potential off-label
human vaccine use in horses. For example, vaccine failure
and fatal encephalitis due to naturally acquired JEV infec-
tion has been reported in a racing horse imported from
Australia into Hong Kong [5]. Cases of equine JE have
the potential to cause significant adverse economic effect
on the horse industry, which is estimated to contribute
greater than $6 billion to the GDP in Australia alone [12].
An inactivated Vero cell culture-derived JEV vaccine
combined with delta inulin adjuvant (JE-ADVAX™) was
previously tested in mice and adult horses and shown
to have superior immunogenicity compared to the now-
discontinued JE-VAX as well as a recently licensed, alum-
adjuvanted cell culture-derived vaccine (JESPECT®, Novartis)
[13]. The primary aim of the present study was to undertake
vaccine efficacy and safety trials of the new JE-ADVAX™
vaccine in pregnant mares and in foals without or with
passively acquired maternal antibodies. A second aim
was to explore the potential ability of the JE-ADVAX™
vaccine to induce cross-reactivity and cross-protection
against two related viruses, Murray Valley encephalitis
virus (MVEV) and a new equine-virulent WNVKUN strain
(strain NSW2011), which appeared in South-East Australia
in early 2011 and caused a large epidemic of equine en-
cephalitis [14,15]. Given the unlikely future development of
equine vaccines specifically against MVEV and WNVKUN,
it would be useful if an adjuvanted JEV vaccine could
provide cross-protection against these related flaviviruses.
In the present report we demonstrate safety and efficacy
of the JE-ADVAX™ vaccine in young foals and pregnant
mares. Foals born to unvaccinated mares responded to the
vaccine with long-lasting humoral immunity, while foals
with passively acquired maternal JEV antibodies had a
blunted response to primary immunization, but after a
vaccine booster as yearlings had a robust JEV-specific
response indicating that memory B cells had been suc-
cessfully primed during the primary immunization des-
pite interference from maternal antibodies.Materials and methods
Antigen and adjuvant
The Vero cell culture-grown inactivated JEV vaccine
(Beijing-1 strain) [16] was obtained from the Kitasato
Institute, Japan. The Advax™ adjuvant was described in
detail in Lobigs et al. [13]. Briefly, Advax adjuvant is
based on microparticulate delta inulin [17], and was ob-
tained from Vaxine Pty Ltd, Adelaide, Australia. Advax™ issupplied as a sterile, preservative-free, fine particulate sus-
pension of delta inulin particles in a phosphate buffer. The
vaccine antigen and Advax adjuvant were mixed together
less than two hours prior to inoculation and the mixture
kept on wet ice until injected.
Animals, vaccination protocol and sample collection
The studies were approved by the University of Queens-
land Animal Ethics Committee (AEC nos. SVS/306/11/
VAXINE and SVS/298/13/VAXINE), and carried out in
accordance with the ARC/NHMRC guidelines for ethical
use of animals in research. A total of 53 thoroughbred
and standard bred horses were enrolled in the studies
(Tables 1, 2, 3 and 4). All horses were held in paddocks
at the UQ Gatton Campus throughout the studies and
received supplementary feed when needed. The first co-
hort of 19 foals, 74–152 days of age at first vaccination,
were born to non-vaccinated mares and were all sero-
negative for flavivirus antibodies at entry into the trial
(Table 3). Twelve foals were vaccinated with the Advax-
adjuvanted JEV-vaccine, while seven foals received the
adjuvant only. Seventeen mares in the second trimester
of pregnancy were enrolled in the second phase, with 11
mares receiving the JEV-antigen plus Advax and six mares
receiving adjuvant only. Two of the JEV-vaccinated mares
had pre-existing antibodies specific for flaviviruses other
than JEV, MVEV or WNV (data not shown; [18]). The
foals born to the mares were subsequently enrolled in the
third phase of the study (see below).
Vaccination was by subcutaneous inoculation on the
rump (first foal cohort) or neck (mares and second foal
cohort) in a volume of 150 μL. For both foals and mares
the initial vaccine dose was 12 μg JEV-antigen plus
20 mg Advax™ and the booster vaccination, given four
weeks later was 6 μg JEV-antigen and 20 mg Advax™.
Blood samples were collected at each vaccination event
and then at intervals of 4–36 weeks for up to 10 months
post vaccination (Figure 1). The foals born to vaccinated
mares were bled at birth, before colostrum uptake, and
again 12 h after colostrum uptake, and a colostrum
sample was obtained from the mares at foaling. This
second cohort of foals was initially vaccinated at 36–83
days of age with a schedule similar to the first foal-
cohort. They subsequently also received one additional
vaccine booster (6 μg JEV-antigen and 20 mg Advax™)
10 months after the initial vaccination and blood samples
were collected 2, 6, 12 and 18 weeks post vaccination. The
six foals born to Advax™-only treated control mares
were left untreated. Two of these unvaccinated foals
were subsequently lost due to study-unrelated causes
(birth complications and trauma, respectively).
Following each vaccine injection the animals were
clinically assessed daily for 3–4 days while kept in small
holding paddocks. The injection sites were inspected and
Table 1 Flavivirus specific antibody levels in foals born to flavivirus antibody-negative mares and vaccinated at
74–152 days of agea
Age at JEV neutralising antibodies MVEV neutralising antibodies WNVKUN neutralising antibodies
Foal # Day 0 Day 28 (boost) Day 56 Day 308 Day 28 (boost) Day 56 Day 308 Day 28 (boost) Day 56 Day 308
1 F11 74 80 20 <20 < 20 < 20 20
5 F11 115 40 160 160 < 20 <20 20 < 20 < 20 < 20
7 F11 108 160 40 <20 < 20 40 < 20
8 F11 132 160 < 20 20 < 20 40 < 20
11 F11 119 160 80 20 < 20 40 < 20
12 F11 81 40 1280 80 < 20 80 < 20 < 20 80 < 20
14 F11 123 320 20 <20 20 20 < 20
15 F11 125 320 < 20 <20 < 20 40 20
17 F11 111 320 20 <20 < 20 < 20 < 20
21 F11 97 320 < 20 20 < 20 < 20 20
26 F11 116 40 1280 80 20 80 20 < 20 < 20 20
30 F11 111 160 20 <20 < 20 < 20 20
Control A 115 < 20 < 20 <20 20 < 20 20
Control G 115 < 20 < 20 <20 < 20 < 20 < 20
aSamples negative in the flavivirus (4G2) blocking ELISA were not tested in the neutralization assays. This included five control foals (B-F), aged 125 to 152 days,
which are not listed in the table.
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demeanor were also recorded. With no adverse reactions
recorded the animals were then returned to the main
paddocks.
Flavivirus serology
Blood samples were collected by venepuncture into ster-
ile vacutainers (BD Biosciences, Franklin Lakes, NJ, USA)
and allowed to clot at room temperature, then centrifuged
at 4 °C for 10 min at 3500 rpm. Procured sera were stored
at −20 °C in sterile cryovials until assayed by ELISA and
virus neutralization following heat inactivation at 56 °C for
30 min. Colostrum samples were centrifuged and the non-
fat fraction collected and heat-treated as for serum before
testing in the ELISA and neutralization assay.
All horse sera and colostrum samples were initially
screened for flavivirus-specific antibodies using an epitope-Table 2 Flavivirus antibody responses in mares vaccinated in






Day 0 (vaccination) 0/11 – – 0/1
Day 28 (booster) 0/11 – – 0/1
Days 56-183 8/11 180 20-320 4/1
Day 230 (7.5 months) 11/11 47 20-80 9/1
Day 331 (11 months) 7/11 26 20-40 4/1
≠mean of titres ≥ 20.
*same two mares (# 10 & 33).blocking ELISA [19,20] with minor modifications as de-
scribed in detail in Prow et al. [18]. Samples showing > 30%
inhibition in this assay were subsequently tested for
neutralizing antibody reactivity to JEV (strain Nakayama),
MVEV (strain 1–51) and WNVKUN (strain NSW2011).
The heat-inactivated test sera were titrated in doubling
dilutions from 1:20 to 1:2560 and colostrum samples in
dilutions from 1:40 to 1:5120 as previously described in
detail [18].
Results
JE-ADVAX™ responses in foals born to naïve mares
In this trial, 19 foals, aged 74–152 days and born to
non-vaccinated, flavivirus sero-negative mares, were en-
rolled. Twelve foals received two vaccinations four weeks
apart with 12 μg and 6 μg JE-ADVAX™, respectively. Six










1 – – 0/11 – –
1 – – 2/11 80 20-80
1 100 20-160 3/11 560 20-1280
1 31 20-80 2/11* 60 20-80
1 40 20-80 2/11* 60 20-80
Table 3 Flavivirus-specific antibodies in colostrum and serum of JE + ADVAX™ vaccinated and unvaccinated mares at
the time of foalinga
Colostrum Serum












2 2560 80 < 40 40 < 20 < 20
5 160 < 40 < 40 20 20 < 20
8 640 80 < 40 20 < 20 < 20
10 640 80 80 40 20 80
11 320 40 < 40 < 20 20 < 20
14 640 80 < 40 20 < 20 < 20
17 320 40 < 40 40 40 40
21 160 40 < 40 < 20 < 20 < 20
26 160 80 < 40 20 < 20 < 20
33 640 80 40 40 40 80
34 640 < 40 < 40 40 < 20 < 20
Control Ab 160 40 < 40 < 20 < 20 < 20
Control B 40 40 < 40 < 20 < 20 < 20
Control C 320 40 < 40 < 20 < 20 < 20
aSamples negative in the flavivirus (4G2) blocking ELISA were not tested in the neutralization assays. This included three control mares (D-F), which are not shown
in the Table.
bEntered trial at time of foaling, having received neither JEV + Advax nor Advax alone.
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some of the foals 1–3 days following subcutaneous injec-
tion on the rump. No reaction was seen in the Advax-only
treated foals. Three foals had flavivirus-specific antibodies
at the time of vaccine-boosting (Table 1), though none
had virus-neutralizing activity. However, four weeks after
the booster 12/12 (100%) of JE-ADVAX™-vaccinated foals
had high serum JEV-neutralizing antibody titres and this
neutralizing activity was still present 8.5 months later
in 9/12 (75%) foals (Table 1). In contrast, cross-reactivity to
MVEVandWNVKUN was generally low or absent (Table 1).
Two control foals had sero-converted to flaviviruses at the
last sampling, 10 months after trial commencement, pre-
sumably due to natural exposure to flaviviruses circulating
in South-East Queensland [18,22,23].
JE-ADVAX™ safety and immunogenicity in pregnant
mares
The JE-ADVAX™ vaccine formulation was previously
shown to be safe and immunogenic in adult horses [13],
however, for licensing purposes it must also be shown to
be safe in pregnant animals [21]. Therefore, 17 mares in
second trimester of pregnancy were enrolled in a trial,
where 11 mares received an initial dose of 12 μg of JEV
antigen mixed with 20 mg of ADVAX™ subcutaneously
in the neck and four weeks later were boosted with 6 μg
of JEV antigen plus ADVAX™. No adverse reactions were
noted, other than mild swelling at the inoculation siteof some mares 1–3 days following the booster vaccin-
ation. Four mares received ADVAX™ only at the two time
points and no reactions to the adjuvant were recorded.
The remaining two mares received neither antigen nor ad-
juvant. Pre-vaccination, two of the pregnant mares had
flavivirus-specific antibodies, detected in the 4G2-blocking
ELISA, however, these antibodies did not neutralize JEV,
MVEV or WNVKUN (Table 2). At the time of vaccine
boosting (four weeks after initial dose), an additional five
mares had developed flavivirus specific antibodies, de-
tected in the blocking ELISA (data not shown), although
none had measurable JEV or MVEV neutralizing anti-
bodies. At this time point one of the mares with pre-
immunization flavivirus antibodies had developed a
WNVKUN-neutralizing titre of 80 (Table 2 and data not
shown). Four weeks after the booster vaccination, 11/11
(100%) of mares had flavivirus-specific antibodies in the
blocking ELISA and of these 8/11 (72%) had developed
JEV-neutralizing antibodies, while only four (36%) and
three (27%) had MVEV- and WNVKUN-neutralizing anti-
bodies, respectively (Table 2). Interestingly, 7.5 months fol-
lowing vaccination all 11 mares (100%) had JEV-neutralizing
antibodies, while nine (82%) and two (18%) had neutralizing
antibodies to MVEV and WNVKUN, respectively (Table 2).
This suggests that either some animals responded slowly to
the vaccine or had been naturally exposed to flaviviruses,
most likely MVEV or Alfuy virus [18,22], thereby providing
a boost to the original vaccine response.
Table 4 Flavivirus specific antibody levels in foals born to vaccinated mares and vaccinated at 36–83 days of age,
followed by booster vaccinations four weeks and approximately one year later













Pre-suckle 0/11 – – 0/11 – – 0/11 – –
Post suckle 10/11 46 < 20-80 8/11 30 < 20-40 3/11 93 < 20-160
Age 13–49 days 3/10* 26 < 20-40 1/10* 40 < 20-40 2/10* 30 < 20-40
Vaccination 3/11 20 < 20-20 2/11 20 < 20-20 1/11 40 < 20-40
Age 36–83 days
Booster 4 weeks post vaccination 2/11 20 < 20-20 3/11 20 < 20-20 2/11 20 < 20-20
Age 64–111 days
4 weeks post booster 10/11 88 < 20-320 10/11 30 < 20-40 1/11 20 < 20-20
Age 93–140 days
7 weeks post booster 3/11 53 < 20-80 6/11 26 < 20-40 3/11 20 < 20-20
Age 114–161 days
10 weeks post booster 5/11 24 < 20-40 0/11 - < 20 1/11 20 < 20-20
Age 137–184 days
~9 months post 1st boost (2nd boost) 0/11 – < 20 0/11 – < 20 0/11 – < 20
Age 332–379 days
2 weeks post 2nd boost 11/11 > 902 160- > 2560 10/11 50 < 20-80 1/11 20 < 20-20
Age 346–393 days
5.5 weeks post 2nd boost 11/11 465 160-1280 7/11 17 < 20-40 0/11 - < 20
Age 370–417 days
14 weeks post 2nd boost 8/11 150 < 20-640 0/11 - < 20 9/11 31 < 20-80
Age 454-501
20 weeks post 2nd boost 7/11 63 < 20-160 0/11 - < 20 0/11 - < 20
Age 498–545 days
*one foal not yet born at this sampling point.
≠mean of titres ≥ 20.
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ation and all had high JEV-neutralizing antibody titres in
the colostrum, even though the serum-titres in two of the
mares at the time of foaling were below the assay cut-off
(Table 3). In 9/11 (82%) of the mares the colostrum anti-
bodies also neutralized MVEV, while in only 2/11 (18%)
mares did the colostrum antibodies neutralize WNVKUN
(Table 3).
None of the control unvaccinated mares or mares
injected with ADVAX™ alone had flavivirus-specific anti-
bodies, based on the pre-vaccination blocking ELISA,
however, three of these mares developed flavivirus specific
antibodies during the trial period (Table 3). As none of
these mares had neutralizing antibodies to JEV, MVEV or
WNVKUN, it is most likely they sero-converted to some of
the other flaviviruses commonly circulating in the area
[18]. Interestingly, the colostrum of these three control
mares did have neutralizing activity towards JEV and
MVEV, but not to WNVKUN (Table 3).JE-ADVAX™ responses in foals born to JEV-immune mares
In the second foal trial, 11 foals born to the JE-ADVAX™
vaccinated mares (Tables 2 and 3) received a similar vac-
cine schedule to that described earlier for the first trial
when they were between 36–83 days old. At vaccination,
six (55%) foals still had measurable passively transferred
maternal serum antibodies to flaviviruses, as detected by
the blocking ELISA, although only three (27%) had measur-
able serum JEV neutralizing titres (Table 4). Nevertheless,
all 11/11 (100%) foals responded to the JE-ADVAX vaccine
with antibodies detectable by the 4G2-blocking ELISA four
weeks after the booster vaccination (Table 4). Of these 10
(91%) had JEV- and 10 (91%) MVEV-neutralizing anti-
bodies after the booster vaccination, but the titres rapidly
decreased and by 10 weeks after the booster vaccination
only 5/11 (45%) foals had low JEV-neutralizing antibody
titres, none had MVEV-specific antibodies and only
one had a low WNVKUN-specific titre (Table 4). Four
foals borne to non-vaccinated mares and left untreated
Figure 1 Schematic of the vaccination schedules for the three cohorts. The numbers under each line refer to days post-vaccination. The timelines
are not to scale.
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the trial (data not shown).
When these 11 vaccinated foals were retested 10 months
after the primary vaccination, only two (18%) had flavivirus-
specific antibodies detectable in the blocking ELISA, but
neither had virus-neutralizing activity (Table 4). The
animals, now yearlings, then received a single booster
vaccination with 6 μg of JE-ADVAX and were bled two,
5.5, 14 and 20 weeks post booster vaccination. All 11/11
animals were already strongly positive in the flavivirus
blocking ELISA two weeks post vaccination, and 11/11
(100%) were confirmed to have JEV-neutralizing anti-
bodies (Table 4), indicating that the original JE-ADVAX
vaccination had primed them for a rapid B cell recall
response despite interference of maternal antibodies.
While the JEV-neutralizing antibody titres declined over
the following 18 weeks, 7/11 horses (63%) still had
JEV-neutralizing antibody titres > 20 at the last bleed
(Table 4). None of the yearlings had MVEV- and
WNVKUN-neutralizing antibodies at the time of the
second booster, but two weeks after the boost 10/11 (91%)
horses had MVEV-neutralizing antibodies (Table 4). The
yearlings remained negative for neutralizing antibodies
to WNVKUN until three months after the booster, when
9/11 (82%) had a detectable titre. The cross-reactive
antibody activity to MVEV and WNVKUN had declined
below the assay cut-off of < 20 by 20 weeks post booster
(Table 4).Discussion
The results of this study corroborate and extend those
of a previous study by Lobigs et al. [13] and show that
the cell culture-derived, inactivated JE-vaccine is safe in
horses of any age and when delivered with the novel
polysaccharide adjuvant Advax elicits a strong JEV-specific
neutralizing antibody response in both pregnant adult
horses and in very young foals which lasts at least 10–11
months in the majority of the animals (Tables 1 and 2).
While a 3rd booster vaccination was not given at that stage,
the results of the vaccine trial in foals with passively ac-
quired immunity suggest that the vaccine delivers robust
priming of a memory B-cell response, which results in a
strong humoral recall response despite serum antibodies
having decreased to undetectable levels (Table 4).
In contrast to the high level of MVEV and WNV cross-
protection seen in mice with JE-ADVAX™ vaccine [24] or
the live Chimerivax-JE vaccine [25], cross-neutralization
of WNVKUN was only present in serum of 27% (3/11) of
mares and in 41% (5/12) of foals immunized with two
doses of JE-ADVAX™ (Tables 1 and 2). In the foals the
low WNVKUN titres detected at day 308 post primary
vaccination may even be the result of boosting by nat-
ural exposure to JEV sero-complex flaviviruses, as MVEV,
WNVKUN and Alfuy virus are known to circulate in the
area where the horses were kept [18,22,23]. However, ex-
tensive JE-ADVAX dose ranging studies have not yet been
performed in horses and hence with a larger vaccine dose
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levels seen in mice may be achieved [24]. An alternative
explanation might be that mice are not ideal models for
equine vaccine responses [26].
As could be expected, the JEV-specific antibody titres
in colostrum far exceeded those in the serum of the mares
at the time of foaling (Table 3). This difference was even
more notable for MVEV cross-reactive antibodies, with
MVEV-neutralizing activity detectable in the colostrum of
82% (9/11) of immunized mares and in serum of 72%
(8/11) of foals 12 h post colostrum uptake, despite be-
ing detectable in the serum of only 45% (5/11) of these
mares (Tables 3 and 4). While this trial was not designed
to assess the half-life of passively acquired immunity, it is
nevertheless a notable finding, as it would suggest that
vaccination of pregnant mares with the JE-ADVAX vac-
cine in areas of Australia where MVEV is endemic might
confer protection of the foals against this almost invariably
fatal infection [22,27-30]. In general, the cross-reactivity to
MVEV was greater than that to WNVKUN. Nevertheless,
the results suggest that it might be possible to further en-
hance flavivirus cross-protection by additional vaccine
boosters, as was seen in the study by Lobigs et al. [13], or
increases in vaccine dose.
Two control mares, receiving Advax adjuvant only,
were apparently naturally exposed to flavivirus(es) some-
time between the start of the trial and foaling, giving rise
to high cross-reactivity to JEV and MVEV in their colos-
trum (Table 3). Similarly, a control mare that received
neither vaccine nor adjuvant, had high JEV- and MVEV-
neutralizing antibody titres in its colostrum despite only
having serum neutralizing activity to Kokobera virus
(titre of 40 [18]), which normally does not confer cross-
protection to JEV serocomplex viruses [18,31]. Two of
the foals born to these three control mares were subse-
quently positive for flavivirus antibodies in the 4G2-
blocking ELISA for a couple of months, but at no point
was JEV- or MVEV-neutralizing activity detected in their
serum (data not shown). This aspect was not further
pursued, but it might be speculated that these were anti-
bodies of low affinity and/or avidity and/or quickly ca-
tabolized in the foals.
The degree of interference with immune responses in
young animals by passively acquired maternal antibodies
may depend on the animal species, antigen type, route
of vaccination and other variables [32-38]. While all the
foals received flavivirus-specific antibodies in colostrum,
resulting in detectable serum JEV-neutralizing antibodies
in 91% of foals at 12 h post suckle, this neutralizing ac-
tivity decreased to below detection level in all but the
three youngest foals by the time of primary vaccination
(Table 4), and all but one foal responded with moderately
high to high JEV-neutralizing titres four weeks after the
second vaccine dose. However, in the presence of maternalantibodies the antibody response to vaccination was
shorter-lived, with only 5/11 (45%) foals still having
JEV-neutralizing antibodies 10 weeks after the booster. Six
months later all but two were negative for flavivirus anti-
bodies in the 4G2-blocking ELISA, but all 11 animals, by
then yearlings, responded to a second booster with a very
rapid and robust antibody response. Thus, while vaccin-
ation at an age where passively acquired antibodies were
still present prevented sustained serum neutralizing anti-
body responses, memory B cells were still induced in these
foals immunized in the presence of passive antibodies, as
reflected in their vigorous response to a single vaccine
boost. This suggests that the apparent “window of suscep-
tibility” created by vaccination in the presence of passively
acquired antibodies, may not in reality be as much of a
problem as generally thought [35,37-39], as even in the
absence of pre-existing serum antibody, the primed mem-
ory B cell response is able to respond rapidly enough to
control any infection. Arthropod-borne viruses initially
replicate at the site of inoculation before spreading haema-
togenously or via the lymphatic system to local lymph
nodes and beyond [40,41]. While the route and mecha-
nisms of neuro-invasion by the encephalitic flaviviruses
are still unknown [42], we recently described a case of
MVEV-encephalitis in a horse, in which MVEV-neutralizing
antibodies were present one week prior to clinical symp-
toms, but not two weeks prior to clinical disease [22]. This
suggests that even in a primary infection the antibody
response to JEV-serocomplex viruses may be relatively
fast, and can be anticipated to be even faster in a recall
response [43]. If this assumption is correct, then primed
animals lacking detectable serum-neutralizing antibodies
might still be protected by a rapid memory B cell recall
response able to neutralize the virus before it spreads
to the central nervous system. This is similar to the results
obtained in JE-ADVAX-immunized beta-2-microglobulin
knockout mice, which were still protected against JEV,
despite having no detectable serum neutralizing antibody
pre-challenge, thanks to a robust recall response and rapid
rise in serum antibody titer in response to the challenge
virus [44]. Future studies should aim to test this hypoth-
esis in horses, since as discussed above, the murine
immune response may not truly reflect that of equines
[26], nor does the disease progression in mice reflect that
seen in natural and experimental infections of horses with
JEV, MVEV and WNVKUN ([22,45-49]; Bielefeldt-Ohmann
et al., unpublished data 2013).
In conclusion, JE-ADVAX™ was safe, well-tolerated and
highly immunogenic in both young foals and in pregnant
mares, in which it induced high titre JEV-specific antibodies
in colostrum, thus ensuring passive transfer of protective
antibodies to the newborn foals. Despite evidence of mater-
nal antibody interference, foals of immune dams developed
strong memory B cell responses to JEV, as reflected in a
Bielefeldt-Ohmann et al. Veterinary Research 2014, 45:130 Page 8 of 9
http://www.veterinaryresearch.org/content/45/1/130robust recall response to a single booster JE-ADVAX
dose as yearlings. Although primarily designed to provide
protection against JEV, some cross-neutralisation against
MVEV and WNV was seen in some of the JE-ADVAX im-
munized horses. Future studies will test modifications to
the vaccination protocol, including increasing the antigen
or adjuvant dose, adding a further booster immunization,
priming with JE-ADVAX and boosting with already li-
censed WNV vaccines [47,50] or with novel WNV vaccine
candidates [48,51-54] to see whether it is possible to induce
cross-protection against a wider spectrum of flaviviruses.
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